TARIS Biomedical

TARIS Biomedical® Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Bladder Cancer

Authors:
Steven Giannos
Date:
Business Wire: August 10, 2016 – LEXINGTON, MA, U.S.A. – TARIS Biomedical, a company developing powerful and targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases, announced today the initiation of a phase 1b clinical trial of TAR-200 (GemRIS™,…

TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Authors:
Steven Giannos
Date:
Business Wire: July 13, 2016 – LEXINGTON, MA, U.S.A. – TARIS Biomedical LLC, a company developing powerful and targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases, announced today the initiation of a phase 1b clinical trial of TAR-200 (GemRIS™) in…

join_crs.jpg